

ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

21 November 2024

ECS Botanics increases NAB loan facility; announces market-leading Medical Advisory Board

VESIsorb[®] on track for November launch

ECS Botanics Ltd (ASX:ECS) (ECS or Company) provides an update on its increased loan facility with NAB, its new Medical Advisory Board, and the advancement of its business-to-consumer (B2C) business with the upcoming launch of VESIsorb[®].

Highlights

- Loan facility increased from \$2.0 million to \$3.2 million with NAB to support working capital requirements of the growing B2C business
- Industry-leading Medical Advisory Board appointed to guide patient-focused activities and education to support innovative technologies such as VESIsorb[®]
- Cannabis soft gel capsules with VESIsorb[®] to launch through B2C brand, Avani

NAB Loan Facility Increase

ECS has secured an increase to its corporate loan facility with NAB from \$2.0 million to \$3.2 million. Strengthening ECS' working capital position provides greater flexibility to scale its B2C operations to meet growing customer demand.

The B2C business requires longer payment cycles compared to the B2B business, with strong B2C sales creating a short-term requirement for additional working capital.

Medical Advisory Board appointments

To strengthen its B2C business, ECS has established a Medical Advisory Board (**MAB**) to provide expert guidance, oversight, and education to the medical industry to support patient outcomes.

All **MAB** members are experienced medical practitioners, widely regarded as thought leaders in medicinal cannabis medicine. They understand the importance of good clinical practice, sound advice, and the value of medicinal cannabis as an option to support patient wellbeing.

The **MAB** is comprised of Dr Rupert Backhouse, Dr Phil Burrell, Dr Natasha Feingold, Dr Charlotte Middleton, Dr Christopher Schneider, Dr Justin Welsh and Dr Jane Chapman.



Biographies of each of these MAB members can be found on the ECS website.

<https://ecs-botanics.com/medical-advisory-board/>

VESIsorb® launch

ECS will launch its first product utilising the advanced delivery system, VESIsorb® this month. VESIsorb® is a patented system that is clinically proven to deliver quicker onset, better absorption, and higher efficiency in cannabis-based products.

'Avani Advanced Cannabis Soft Gel Capsules Powered by VESIsorb®', will be the first product to launch in the Avani range - ECS' direct-to-consumer brand, with rollout to be supported by the B2C sales team. The launch rounds out ECS' B2C offering, that now includes, a premium line, Terphogz™, mid-market range, Avani and budget line, OzSun.

ECS holds a ten-year exclusive license agreement for VESIsorb® from global cannabis company, Geocann®, covering Australia, New Zealand, the United Kingdom, and extends to Europe for ECS product formulations.

ECS Managing Director, Nan-Maree Schoerie, said:

"We are excited to announce the formation of our Medical Advisory Board. Their expertise will be crucial as we continue rolling out our B2C offerings, ensuring patients achieve the best outcomes with our medicinal cannabis products."

"Each advisor brings a profound understanding of medicinal cannabis and its impact on patient well-being. The MAB will play a pivotal role in the success of our entire ECS product line, including the new Avani Advanced Cannabis Soft Gel Capsules. Powered by VESIsorb®, these capsules offer four times the absorption rate and act three times faster compared to current market options."

"I look forward to this phase of growth, supported by a team of medicinal cannabis experts as we expand our range of high-quality, Australian-grown medicinal cannabis products to reach more patients worldwide."

Authorised for release by Nan Maree Schoerie, Managing Director.

-ENDS-

Investors

Eric Kuret, Automic Group

P: +61 417 311 335

E: eric.kuret@automicgroup.com.au

Media

Michelle Audsley, Automic Group

P: +61 402 008 929

E: michelle.audsley@automicgroup.com.au



About ECS BotaniCS Holdings Ltd

ECS BotaniCS Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.

For personal use only